Journal
GYNECOLOGIC ONCOLOGY
Volume 165, Issue 1, Pages 30-39Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2022.01.021
Keywords
Ovarian cancer; BH3 mimetics; Platinum resistance; Early phase study
Categories
Funding
- French Cancer Research Hospital Program [PHRC11-015]
- ARCAGY GINECO Intergroup (academic clinical research group specializing in gynecological oncology)
- Ligue contre le Cancer (Mariapia Bressan award)
- ARCAGY GINECO intergroup
Ask authors/readers for more resources
This study aimed to evaluate the efficacy of Navitoclax monotherapy in patients with high-grade serous platinum-resistant ovarian tumors. The results showed that Navitoclax monotherapy had promising activity in these patients.
Background. There are limited treatment options for ovarian cancer patients with early relapse after platinum chemotherapy. In preclinical studies, we previously demonstrated the promising activity of ABT-737, a Bcl-2/Bcl-xL anti-apoptotic protein inhibitor, in chemo-resistant ovarian cancer cells and tumors, suggesting its potential activity in platinum-resistant patients. Methods. We conducted a prospective multicenter single-arm phase II study to assess the efficacy of Navitoclax (orally available ABT-737 analogue) monotherapy in 46 heavily pretreated (2-12 lines, median = 4) patients with high-grade serous platinum-resistant ovarian tumors. Navitoclax was administered at the daily dose of 150 mg during a lead-in period (7-14 days) and then increased to 250 mg daily in the absence of dose-limiting thrombocytopenia (
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available